Cue Biopharma gains on FDA's 'fast track' tag for cancer drug candidate

Cue Biopharma

04/10/2022 14:42

** Shares of Cue Biopharma Inc  CUE.O  rise ~11% to $2.66 in
early trade 
    ** Says U.S. FDA has granted its experimental drug, CUE-101,
fast track designation for treatment of a type of head and neck
cancer  urn:newsml:reuters.com:*:nGNXmLf3P
    ** Designation can help with more frequent interactions with
 FDA to discuss drug's development plan, including eligibility
for accelerated approval and priority review if supported by
clinical data
    ** Drug is currently being studied in early-stage trials as
a monotherapy and in combination with Merck and Co's  MRK.N 
cancer drug, Keytruda, for treating recurrent/metastatic head
and neck squamous cell carcinoma
    ** Up to Monday's close, stock had fallen ~79% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))